Massachusetts General Hospital
The goal of this study is to refine and test a digital intervention named WAYPOINT to help patients monitor and manage symptoms after CAR-T therapy. The main question this study aims to answer is whether this intervention can be used as planned (i.e, feasible) and whether it is helpful and easy to use for both patients and clinicians (i.e., acceptable).
This study will examine the feasibility and acceptability of a digital symptom monitoring and management intervention (WAYPOINT) for improving symptom burden, quality of life and self-efficacy among patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. We will first refine WAYPOINT and then conduct a single-arm trial. During the refinement phase, we will enroll 15 patients and 10 clinicians to gather feedback on WAYPOINT and inform further development of the intervention. Following refinement, we will enroll 30 patients and 10 clinicians in a single arm study to examine the…
Patient Inclusion Criteria: * Adult patients (at least 18 years old) diagnosed with hematological cancer * Treated with CAR-T as standard of care at Massachusetts General Hospital * Ability to speak and read English to use WAYPOINT and respond to the questionnaires with minimal assistance requried from an interpreter or a family member Patient Exclusion Criteria: * Patients with a major untreated psychiatric or cognitive conditions which the treating clinician believe prohibits the ability to participate in study procedures Clinician Inclusion Criteria - Healthcare clinicians (e.g., physic…
Digital symptom monitoring and management intervention that includes psychoeducation and symptom monitoring, with alerts to the clinical team.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.